A 2006 study found that 42% of phase III trials failed between 1990-2002. Fifty percent of these were because the molecule could not be shown to be better than placebo, 30% of the failures were due to safety issues and 20% due to an inability to show efficacy or safety benefits over existing products.
Tā ka būtu pārspīlēti teikt, ka tā būtu nolaidība eksperimentu plānojot.